One Drop expands machine learning models beyond glucose, accurately predicting average blood pressure one week in advance, according to study results unveiled at #AHA2021. The strength and diversity of our predictive capabilities demonstrate utility for members needing proactive support and employers seeking lowered costs related to #hypertension and other chronic conditions. To our knowledge, this is the first study to demonstrate accurate blood pressure predictions one week out.
One Drop’s Post
More Relevant Posts
-
The Fall 2023 DiabetesMine Innovation Days (#DData) are happening next week in San Diego, CA, Nov 9-10. You're invited! D-Data—the birthplace of the #WeAreNotWaiting movement—connects healthcare leaders and the innovators behind cutting-edge digital health tools, next-gen medical devices, and programs designed to take #diabetes care to the next level. #Data2023 is sponsored by UC San Diego Health. Interested in attending? Contact Amy Tenderich at info@diabetesmine.com. *Discounts are available to patient entrepreneurs and advocates, researchers, and nonprofits. https://ddataexchange.com/
-
-
Can the order in which you eat your food help prevent #diabetes? According to a new study in Nutrients MDPI, the answer is yes. One Drop clinical health coach Hanna Rifkin, RD, CDCES, explains the link between #foodsequencing and blood glucose levels. Plus, tips for experimenting with the increasingly popular eating practice. Learn more: bit.ly/46KFmdt
-
-
In the United States, nearly 1 in 3 adults (30.7%) are overweight; more than 2 in 5 adults (42.4%) have obesity. Despite the growing popularity of GLP-1 medications, employers are twice as likely to cover bariatric surgery than a GLP-1 for weight loss. Justifications for narrow coverage hinge on outrageous costs and a lack of evidence for the long-term effectiveness of anti-obesity drugs like Wegovy. This month, Novo Nordisk, creator of Wegovy (semaglutide), challenged a long-standing narrative that for people without diabetes, #GLP1 medications are merely lifestyle products that offer cosmetic, not medical, benefits. Beyond #weightloss, their five-year clinical trial showed significant cardiovascular health benefits for patients who stay on Wegovy, citing a 20% reduction in risk of heart attack, strokes, and cardiovascular deaths. Reuters #healthcarenews
-
Did you know? The Dexcom G7 seamlessly integrates with One Drop thanks to direct API integration. Continuous glucose data from Dexcom can be automatically streamed to the One Drop app, helping members living with #diabetes see a fuller picture of their health. Continuous glucose monitoring (#CGM) is a game changer for people living with diabetes. This technology, combined with One Drop’s one-on-one coaching, glucose predictions, and comprehensive data tracking, gives members a fuller picture of their health. https://lnkd.in/epedRiiB
-
-
GLP-1 medications like Ozempic, Wegovy, and Trulicity offer incredible results like lower blood sugar and weight loss. But these groundbreaking medications may come with uncomfortable side effects. In our latest blog post, we dig into the 16 recommendations published in the Journal of Clinical Medicine for preventing and managing these gastrointestinal issues in people treated with #semaglutide or other #GLP1 receptor agonists. Read More: joinonedrop.com/3Omt8zO
-
-
We are proud to announce One Drop is a 2023 #PrixGalien USA Award nominee for Best Digital Health Solution. The Galien Foundation fosters, recognizes, and rewards the development of next-gen innovative treatments and technologies designed to save lives and improve humanity. To receive recognition from The Galien Foundation is a great honor. Winners will be announced during the Prix Galien USA Forum on October 26, 2023, at the Alexandria Center for Life Science in New York City.
The Galien Foundation Announces 2023 Prix Galien USA Nominees for "Best Digital Health Solution," "Best Medical Technology," "Incubators, Accelerators and Equity," and "Best Startup"
prnewswire.com
-
Whether managing one or multiple chronic conditions, the key is to have a holistic view of your health—from your weight to your heart and blood sugar. With One Drop's data tracking tools and integrations with Dexcom, Apple, Withings, and more, members can view workouts, food, medication, blood pressure, glucose levels, and more. Data is power. When we own our health data, we have the power to make educated self-care decisions and see results. Learn more: https://lnkd.in/eQzBqXSs
-
Overeating is a leading cause of obesity, making appetite-suppressing semaglutide a powerful weight loss drug. New evidence published in Scientific American suggests that besides reducing food cravings, Ozempic by Novo Nordisk and similar semaglutide medications may also alleviate intense urges to use substances like nicotine and alcohol by targeting the brain circuitry involved in addiction. While hopeful about its promise, psychiatrists raise valid concerns that semaglutide might be too effective at dampening pleasure and reward pathways. #healthcarenews #glp1 #semaglutide
Could New Weight-Loss Drugs like Ozempic Treat Addiction?
scientificamerican.com
-
Diabetes rates are projected to more than double by 2050—the main reason: #obesity. Access to GLP-1 medications is more important than ever. Source: The Lancet
More than 1 billion people are projected to have diabetes by 2050
washingtonpost.com
-
If you live with a heart condition such as high blood pressure, it's important to know how to distinguish heat stroke from other potentially less serious heat-related conditions, such as heat cramps and heat exhaustion. Find tips on staying safe and cool in hot weather on the blog: https://ow.ly/uv8Y50P1IAy
-
